Physician profile
Michael A Herrera
NPI 1871610774
$1,501.67
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $676 · 2021: $40.01 · 2022: $21.89 · 2023: $64.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $212.05 | 2019-2020 | |
| Amgen INC. | $165.79 | 2019-2020 | |
| Glaxosmithkline, LLC. | $124.38 | 2019-2020 | |
| Novo Nordisk INC | $105.66 | 2019-2020 | |
| Abbott Laboratories | $97.43 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.55 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.47 | 2019-2020 | |
| Tg Therapeutics, INC. | $64.57 | 2023 | |
| Lilly USA, LLC | $61.40 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $53.76 | 2019 | |
| Topcon Healthcare Solutions, INC. | $49.09 | 2019 | |
| Eisai INC. | $46.23 | 2020 | |
| Boston Scientific Corporation | $42.21 | 2020 | |
| Kaleo, INC. | $25.31 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.94 | 2019 | |
| Medtronic Minimed, INC. | $22.42 | 2019 | |
| Optinose US, INC. | $21.89 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.72 | 2020 | |
| Edwards Lifesciences Corporation | $20.67 | 2020 | |
| Sunovion Pharmaceuticals INC. | $19.10 | 2020 | |
| Ironwood Pharmaceuticals, INC | $15.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.51 | 2019 | |
| Depuy Synthes Sales INC. | $15.49 | 2019 | |
| Cranial Technologies, INC | $14.77 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $14.34 | 2019 | |
| Genentech USA, INC. | $13.37 | 2019 | |
| Shire North American Group INC | $12.70 | 2019 | |
| Zyla Life Sciences, INC. | $11.25 | 2020 | |
| Merck Sharp & Dohme LLC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.